Skip to content

US · COYA · BIOTECHNOLOGY

Coya Therapeutics, Inc. (COYA) intrinsic value and stock valuation

$2.95as of 2026-11-21 · Mkt cap 82.85M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Coya Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values COYA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from COYA’s statements →

Coya Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Houston, TX 77057 coyatherapeutics.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$7.95M
20202025
Net income
-$-21.23M
20202025
Free cash flow
-$-10.74M
20202025
Total equity
$43M+39% 5y CAGRd
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$7.95M$3.55M$6M$0.00$0.00
Operating income-$-20.27M-$-17.25M-$-7.9M-$-9.81M-$-4.87M
Net income-$-21.23M-$-14.88M-$-7.99M-$-12.24M-$-4.89M
EPSd-$-1.27M-$-976.38K-$-786.42K-$-1.23M-$-740.91K
Operating cash flow-$-10.74M-$-10.29M-$-11.19M-$-7.24M-$-3.9M
Capital expenditure$0.00$0.00$0.00$0.00-$-140K
Free cash flow-$-10.74M-$-10.29M-$-11.19M-$-7.24M-$-4.04M
Total assets$50M$44.4M$41.3M$8.4M$4.79M
Total debt$0.00$0.00$0.00$13M$0.00
Net debt-$-46.82M-$-38.34M-$-32.63M$7.03M-$-4.34M
Total equity$43M$39.6M$35.6M-$-8.39M$3.64M
Cash and short-term investments$46.8M$38.3M$32.6M$5.93M$4.34M
Income statement
20252024202320222021
Revenue$7.95M$3.55M$6M$0.00$0.00
Cost of revenue$30K$11.9M$5.5M$4.41M$0.00
Gross profit$7.92M-$-8.31M$500K-$-4.41M$0.00
Research and development expenses$16.7M$11.9M$6.04M$4.94M$2.54M
Selling, general and administrative expenses$11.5M$8.89M$7.83M$4.85M$2.31M
Other expenses$0.00-$-11.84M-$-5.47M-$-4.39M$20K
Operating expenses$28.2M$8.94M$8.4M$5.4M$4.87M
Cost and expenses$28.2M$20.8M$13.9M$9.81M$4.87M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$30K$30K$30K$30K$20K
Ebitda-$-21.2M-$-17.2M-$-7.33M-$-9.26M-$-4.88M
Operating income-$-20.27M-$-17.25M-$-7.9M-$-9.81M-$-4.87M
Total other income/expenses, net-$-960K$1.65M$640K-$-2.43M-$-20K
Income before tax-$-21.22M-$-15.6M-$-7.26M-$-12.24M-$-4.89M
Income tax expense$0.00-$-720K$720K$0.00$0.00
Net income-$-21.23M-$-14.88M-$-7.99M-$-12.24M-$-4.89M
Weighted average shares outstanding$16.7M$15.2M$10.2M$9.95M$6.6M
Weighted average diluted shares outstanding$16.7M$15.2M$10.2M$9.95M$6.6M
Balance sheet
20252024202320222021
Cash and short-term investments$46.8M$38.3M$32.6M$5.93M$4.34M
Net receivables$0.00$730K$7.5M$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$49.9M$44.3M$41.2M$7.18M$4.58M
Property, plant and equipment, net$10K$40K$70K$90K$120K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$10K$40K$70K$1.21M$210K
Total assets$50M$44.4M$41.3M$8.4M$4.79M
Accounts payable$1.06M$1.59M$1.16M$1.82M$860K
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$1.2M$850K$920K$0.00$0.00
Total current liabilities$5.87M$3.82M$5.05M$3.82M$1.15M
Long-term debt$0.00$0.00$0.00$13M$0.00
Deferred revenue, non-current$1.05M$950K$570K$0.00$0.00
Total non-current liabilities$1.05M$950K$570K$13M$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$6.92M$4.77M$5.63M$16.8M$1.15M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-61.96M-$-40.74M-$-25.86M-$-17.87M-$-5.62M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$43M$39.6M$35.6M-$-8.39M$3.64M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$13M$0.00
Net debt-$-46.82M-$-38.34M-$-32.63M$7.03M-$-4.34M
Cash flow statement
20252024202320222021
Net income-$-21.23M-$-14.88M-$-7.99M-$-12.24M-$-4.89M
Depreciation and amortization$30K$30K$30K$30K$20K
Stock-based compensation$4.29M$2.66M$870K$210K$230K
Change in working capital$3.88M$1.88M-$-4.64M$750K$740K
Accounts receivable$0.00$7.5M-$-7.5M$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-530K$480K$300K$850K$670K
Net cash provided by operating activities-$-10.74M-$-10.29M-$-11.19M-$-7.24M-$-3.9M
Investments in property, plant and equipment-$-1.16M$0.00$0.00$0.00-$-140K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-1.16M-$-30K-$-540K-$-530K-$-140K
Common stock issued$20.4M$14M$38.3M$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$20.4M$16M$38.4M$9.36M-$-340K
Net change in cash$8.48M$5.71M$26.7M$1.59M-$-4.38M
Cash at end of period$46.8M$38.3M$32.6M$5.93M$4.34M
Operating cash flow-$-10.74M-$-10.29M-$-11.19M-$-7.24M-$-3.9M
Capital expenditure$0.00$0.00$0.00$0.00-$-140K
Free cash flow-$-10.74M-$-10.29M-$-11.19M-$-7.24M-$-4.04M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Coya Therapeutics, Inc.

        Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutic agents that fine-tune the function of regulatory T cells (Tregs). Its therapeutic pipeline leverages diverse approaches, including biologics designed to enhance Treg activity, Treg-derived exosomes, and personalized autologous Treg cell therapies. Among its lead candidates is COYA 101, an autologous regulatory T-cell product that has successfully completed Phase 2a clinical trials for treating Amyotrophic Lateral Sclerosis (ALS). Moving towards Investigational New Drug (IND) applications are two key candidates: COYA 301 and COYA 302. COYA 301 is a Treg-enhancing biologic aimed at treating Frontotemporal Dementia. Meanwhile, COYA 302 is a dual-action biologic combination, suitable for subcutaneous or intravenous delivery, engineered to not only boost Treg function but also to diminish harmful T effector cell activity and activated macrophages in neurodegenerative and autoimmune disorders. Additionally, Coya has earlier-stage programs, including COYA 201, an allogeneic (off-the-shelf) Treg exosome candidate in preclinical development for a range of neurodegenerative, autoimmune, and metabolic conditions. Its pipeline also features COYA 206, an antigen-directed Treg-derived exosome product, currently in the discovery phase. Established in 2020, Coya Therapeutics maintains its headquarters in Houston, Texas.

        CEO
        Arun Swaminathan
        Employees
        8
        Beta
        0.60

        Explore

        Frequently asked questions

        What is the intrinsic value of Coya Therapeutics, Inc. (COYA)?

        Coya Therapeutics, Inc. (COYA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is COYA undervalued?

        COYA trades at a price of $2.95 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.